Page 272 - 2021_05-Haematologica-web
P. 272
1492
Letters to the Editor
A
B
C
Figure 1. Patients with acute myeloid leukemia with CEBPA double mutations had more favorable outcomes only when treated with intermediate-dose cytarabine induction. (A) Relapse-free survival, (B) event- free survival, and (C) overall sur- vival are shown for patients with CEBPA double mutations and other types of acute myeloid leukemia by receipt of interme- diate-dose or conventional-dose cytarabine induction. AML: acute myeloid leukemia: HR: hazard ratio; 95%CI: 95% confi- dence interval.
haematologica | 2021; 106(5)
